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Several  lines  of evidence  show  that  suitably  stimulated  mononuclear  phagocytes 
synthesize  and  secrete  an  activator  of the  serum  proenzyme  plasminogen  (1).  The 
production of plasminogen activator by these cells appears to be correlated with their 
involvement  in  inflammatory  reactions:  macrophages  obtained  from  inflammatory 
exudates,  or exposed in vitro to inflammatory agents such  as asbestos fibers, phorbol 
myristate  acetate,  or  concanavalin  A,  secrete  substantial  amounts  of this  enzyme, 
whereas cells obtained from noninflamed peritoneal cavities secrete little or none (1-4). 
Furthermore, low concentrations of anti-inflammatory steroids, or the mitotic inhibitors 
colchicine and vinblastine, block the production of this enzyme (5).  Based on these and 
other observations, it has been suggested that plasminogen activator is involved in the 
migration of mononuclear phagocytes (5). 
Polymorphonuclear leukocytes (PMNs) 1 have many properties in common with mono- 
nuclear phagocytes: both cell types are migratory, phagocytic, and capable of digesting 
endocytosed materials and microorganisms. Like monocytes, PMNs  are recruited from 
the blood stream  and migrate into sites of inflammation. In contrast to  mononuclear 
phagocytes, PMNs are relatively short lived, and they are considered to be terminally 
differentiated cells, with little if any biosynthetic capacity. The proteolytic potential of 
PMNs was recognized by Opie as early as 1905 (6).  Human PMNs contain elastase (7), a 
chymotryptic activity (8),  and collagenase  (9).  In addition, histochemical observations 
have  shown  that  PMNs  can  lyse plasminogen-rich,  but  not  plasminogen-poor fibrin, 
suggesting that these cells contain a plasminogen activator (10). 
We report here the identification and partial characterization  of plasminogen 
activator from human  PMNs  and describe some factors that govern its secretion. 
We have  found that  secretion can be modulated  during  short-term  cell culture 
by  some  of  the  same  agents  that  modulate  enzyme  production  by  mouse 
macrophages. 
Materials  and Methods 
Materials.  Reagents were obtained as follows: heparin (Bio-Heprin, Ries Biologicals, Inc.); 
Dextran T500 and  Ficoll 400  (AB,  Pharmacia  Fine Chemicals,  Piscataway,  N.  J.);  Hypaque 
* Supported in part by grants from the National Institutes of Health (CA-08290), the American 
Cancer Society, Inc. (ACS PDT 1H), and The Rockefeller Foundation. 
1 Abbreviations used in this paper: AT-FBS, acid-treated fetal bovine serum; CM, conditioned 
medium; Con A, Concanavalin A; DFP, diisopropylfluorophosphate; FBS, fetal bovine serum; 
MEM,  minimal essential medium;  PBS,  phosphate-buffered saline;  PMA,  phorbol  myristate 
acetate; PMNs, polymorphonuclear leukocytes; SDS, sodium dodecyl sulfate; TLCK, N-a-p-tosyl- 
L-lysine chloromethyl ketone; TPCK, L-l-tosylamide-2-phenylethyl-chloromethyl  ketone. 
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(Winthrop Laboratories, New York); N-acetyl-(ala)4-chloromethyl ketone was kindly provided by 
Dr.  J.  Powers,  Georgia Institute of Technology,  Atlanta,  Ga.;  elastase  (purified elastase from 
swine  pancreas,  72.7  U/rag,  Worthington Biochemical  Corp.,  Freehold,  N.  J.); p-nitrophenyl 
phosphate (Sigma Chemical Co., St.  Louis, Mo.); Dulbecco's minimal essential medium (MEM) 
and fetal bovine serum  (FBS; GIBCO,  Grand Island, N.  Y.); acrylamide, bis-acrylamide, N,N, 
N'N'-tetramethylethylenediamine and ammonium persulfate  (Eastman Kodak Co.,  Rochester, 
N. Y.); concanavalin A  (Con A) crystallized three times (Miles Laboratories Inc., Elkhart, Ind.). 
Phorbol myristate acetate (PMA) and phorbol were the gifts of Dr. S. Belman, New York Univer- 
sity Medical Center, N. Y.; fibrinogen, dibutyryl-cAMP, cGMP, 8-bromo-cGMP, dibutyryl cGMP, 
dexamethasone,  cycloheximide,  and  elastin  were  all  from  the  Sigma  Chemical  Co.;  cholera 
enterotoxin (Schwartz/Mann, Div. Becton, Dickinson & Co., Orangeburg, N. Y.); actinomycin D 
(Aldrich Chemical  Co.,  Inc.,  Milwaukee,  Wis).  All  other reagents were  of the  highest grade 
available. 
Preparation of Cells.  Human peripheral blood PMNs were obtained from heparinized (2 U/ 
ml) blood of healthy volunteers and purified by a method derived from that of BSyum (11): 1/5 vol 
of Dextran T500 (6% wt/vol in 0.9% NaC1) was mixed with the freshly drawn blood, and the red 
cells  allowed  to  sediment  for  45  rr~n  at  37°C.  The  plasma,  containing white  blood  cells  and 
platelets,  was  layered  over  a  solution  of 6.35%  wt/vol  Ficoll  400  and  10.03%  Hypaque,  and 
centrifuged for 30 rain at 500 g  at 4°C.  The PMNs and some contaminating erythrocytes were 
found as a  pellet at the bottom of the tube, whereas the lymphocytes, monocytes, and platelets 
remained  at  the  plasma/Ficoll-Hypaque  interface.  The  pellet was  resuspended  in  phosphate- 
buffered saline (PBS),  washed by centrifugation (300 g,  5  rain), and the erythrocytes lysed in 
0.83%  NH4C]  (pH  7.4).  After  resuspending  and  washing  in  Dulbecco's  MEM,  the  cells  were 
counted in T~irk's solution, or stained either with Giemsa, or with trypan blue. This method gave 
over  99%  of PMNs,  of which  more  than  95%  were  viable,  as  estimated  by  their  capacity  to 
exclude trypan blue. During the entire preparation procedure, and during culture, the cells were 
never exposed to  glass,  and all manipulations were  performed using plasticware.  All cultures 
were performed at 37°C,  in a  5% CO2-95%  air atmosphere. 
Fibrinolytic Activity.  The fibrinolytic activity of purified PMNs was determined by culturing 
the cells in 125I-fibrin-coated Linbro wells  (see below). The cells were plated in 1 ml Dulbocco's 
MEM supplemented with 5% FBS or with 5% plasminogen-depleted FBS (12),  in the presence or 
absence of Con A  or PMA.  Fibrinolysis was estimated by withdrawing samples of medium and 
assaying them for solubilized radioactivity. 
Preparation of Conditioned Media (CM).  Purified PMNs (1-10 ×  106/ml)  were cultured either 
in Dulbecco's MEM supplemented with 1% plasminogen-depleted acid-treated (1) FBS (AT-FBS) 
or in Hepes buffered Gey's salt solution (for assay of alkaline phosphatase), in Linbro wells (FB 
16-24TC).  The  cultures  were  incubated  in  the  presence  of the  compounds  to  be  assayed  as 
indicated.  At the end of the incubation period the CM were collected, the cells sedimented by 
centrifugation (500 g, 5 rain), and the pellet either discarded or lysed (see below) and assayed for 
enzymatic activity. The CM were frozen and stored at -20°C until assayed. 
Preparation of Cell Lysates.  Purified PMNs (1.5  ×  106) were lysed in 0.5% (vol/vol) Triton X- 
100 in the presence or absence of  N-acetyl-(ala)4-chloromethyl ketone (2 mM) and soybean trypsin 
inhibitor (100 ~g/ml), and centrifuged at 500 g  for 6 min; the supernate was then electrophoresed 
in a  sodium dodecyl sulfate (SDS) 11% polyacrylamide gel, and the gel analyzed for fibrinolytic 
activity (see below). 
Alternatively,  Dulbecco's  MEM  supplemented  with  1%  plasminogen-depleted  AT-FBS,  or 
Hepes buffered Gey's salt solution, containing 5  ×  106 PMNs/ml,  were made 0.5% in Triton X- 
100,  and then frozen and thawed rapidly three times. After clearing by centrifugation (500 g,  10 
min), these cell lysates were assayed immediately for enzymatic activity. 
Detection of  Plasminogen Activator Secretion by Single Cells.  The proportion of cells secreting 
plasminogen activator was determined by a  casein-agar overlay procedure previously described 
(4).  PMNs  (5  ×  103) were plated in 60-mm tissue culture dishes  (Falcon 3002,  Falcon Plastics, 
Oxnard,  Calif.)  in  1 ml of Dulbecco's MEM  supplemented with  1%  plasminogen  depleted AT- 
FBS, in the presence or absence of dexamethasone. After 3 h of incubation, Con A or PMA were 
added where required,  and  1 h  later the medium was removed and the plates overlaid with  a 
casein-agar mixture containing dexamethasone and/or Con A or PMA as indicated; the overlay 
mixture  was  prepared  either  with  or  without  purified  human  plasminogen  (20  ftg/ml).  The GRANELLI-PIPERNO,  VASSALLI,  AND  REICH  1695 
cultures were fxed and stained 5 h  later. The proportion of cells surrounded by lytic zones was 
determined microscopically in triplicate cultures by scoring 200 cells from each culture. 
Preparation of ~nl-Fibrin-Coated Wells.  ~sSI-Fibrin-coated wells of Linbro disposo trays (FB16- 
24TC) were prepared as described (5).  Each well contained approximately 20 ~g l~I-fibrin (5,000 
cpm//~g).  The  amount  of  12~I-fibrin  solubilized  is  expressed  as  the  percentage  of  the  total 
radioactivity that can be released by an excess of trypsin. 
Enzyme Assays.  Plasminogen activator (5), lysozyme (13, 14), and fl-glucuronidase (15) were 
assayed as described. Alkaline phosphatase activity was tested using p-nitrophenyl phosphate as 
a  snbstrate  (16).  Elastinolytic activity was  measured as described by Rifkin et al.  (17),  using 
Sepharose-bound ~2SI-elastin as substrate. 
Polyacrylarnide Gel Electrophoresis.  SDS-polyacrylamide  gel electrophoresis was performed 
as described by Laemmli  (18).  Samples of CM or cell lysates were mixed with double strength 
sample buffer (0.125 Tris  HC1  pH  6.8,  5% SDS;  20% glycerol),  and applied to  a  0.1%  SDS-11% 
polyacrylamide slab gel using a  4% polyacrylamide stacking gel. Electrophoresis was conducted 
at a  constant current of 8  mA for 15 h  at room temperature.  The gel was then processed and 
assayed  for  fibrinolytic  activity  in  the  presence  and  absence  of plasminogen,  by  a  method 
described fully elsewhere. 2 
In brief, the gel was layered onto the surface of a  fibrin agar gel which is opaque due to the 
presence of fibrin.  Fibrinolytic activity was monitored visually by dark-field illumination and 
could be observed as gradually enlarging clear areas developing in the surrounding opaque fibrin- 
agar layer.  After a  desired degree of fibrinolysis was observed, the electrephoretic gel was re- 
moved and the fibrin-agar layer was fixed and stained with amido-black (0.1% in methanol-acetic 
acid), and then destained. 
Results 
Fibrinolysis by Cultured PMNs.  The fibrinolytic activity of purified PMNs 
was  measured  after  plating  these  cells  in  125I-fibrin-coated  culture  wells. 
Fibrinolysis progressed linearly with time, and was proportional to cell concen- 
tration up to 5  ×  10  5 cells per well (Fig.  1). In the absence of plasminogen,  the 
fibrinolytic activity was always lower, by a factor of 2- to 10-fold, varying from 
experiment  to  experiment  (Figs.  1-2).  This  suggested  that  these  cells  could 
promote fibrinolysis  by at least two different pathways; one of these required 
the presence of plasminogen and was therefore presumably due to plasminogen 
activator(s),  and the  other  was  independent  of the presence  of plasminogen, 
and hence due to a different enzyme(s). 
The  fibrinolytic  activity  of purified  mononuclear  cells  was  much  smaller 
than  that  of PMNs:  1  ×  105  mononuclear  cells  did  not  promote  detectable 
fibrinolysis  during  the  first  8  h  of  assay.  Inasmuch  as  the  proportion  of 
mononuclear cells  in the purified  PMN populations did not exceed  1% of the 
total,  this  demonstrated  that  the  fibrinolytic  activity  observed  was  due  to 
PMNs and not to contaminating mononuclear cells. 
The  plasminogen-dependent  fibrinolytic  activity  was  selectively  stimulated 
by incubation of the cells in the presence either of the lectin Con A  (10  -~ M) or 
of low concentrations  of the tumor promoter and inflammatory  agent PMA (8 
×  10 -1°  M)  (Fig.  2).  The  extent  of this  stimulation  was  somewhat  variable: 
preparations of PMNs that exhibited a rather high '~spontaneous" plasminogen- 
dependent fibrinolytic activity could not be stimulated as much as preparations 
that had only very low spontaneous activity; this stimulation varied, therefore, 
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FIG.  1.  Fibrinolysis by purified human PMNs. Serial dilutions of cells were cultured in 
125I-fibrin coated wells in 1 ml Dulbecco's MEM supplemented with 5% AT-FBS (  ) or 
5%  plasminogen-depleted AT-FBS  (---).  Fibrinolysis was  estimated  by  withdrawing 
aliquots of medium at various times, and assaying them for solubilized radioactivity, as 
described in Materials and Methods. •  e, 1 x  10  ~ cells/ml; A  ~, 7.5 x  105 cells/ml; 
[]  rT, 5 x  lO  s cells/ml; ©  O, 2.5  x  10  5 cells/ml; x  x, 1 x  10  5 cells/ml; e-  -e, 
1 x  10  ~. 
from  experiment  to  experiment  between  2-  and  10-fold2  In  contrast,  the 
plasminogen-independent  fibrinolytic  activity  was  always  totally  unaffected 
under these conditions. 
Higher  concentrations  of PMA,  but  not  of Con A  (up  to  10  -s M),  caused  an 
increase in plasminogen-independent  fibrinolysis: in the presence of 1.6  ×  10 -9 
M  PMA  an early increase in plasminogen-dependent  fibrinolysis was followed 
after  2-3  h  by  a  marked  increase  in  plasminogen-independent  lysis.  Even 
higher  concentrations  of PMA  (1.6  ×  10 -8  M)  caused  a  still  more  rapid  and 
short-lived  increase  in  plasminogen-independent  fibrinolysis;  this  could  be 
detected within  30 min  after addition of PMA,  and was practically terminated 
by 2  h  (Fig. 2). 
Phorbol,  an analogue  of PMA  that  is inactive both as a  tumor  promoter  and 
as an inflammatory  agent,  did not affect fibrinolysis by PMNs. 
The  viability  of PMNs  cultured  under  these  conditions  was  estimated  by 
their ability to exclude trypan  blue.  Most of the cells cultured in the absence or 
presence  of Con  A  (10 -7 M)  or low concentrations  of PMA  (8  x  10 -1° M) were 
viable  throughout  all  of the  experiments:  after  8  h  over  95%  of these  cells 
excluded trypan  blue. In contrast, higher concentrations of PMA  (1.6  x  10 -8 M) 
dramatically  reduced the viability of the cells: whereas  after 2  h  of incubation 
3 The reasons for this variability are not clear, but it should be recalled that the purification 
of PMNs involved exposure of the cells to Dextran and Ficoll, compounds known to activate the 
complement system, and hence perhaps capable of generating yet undefined mediators affecting 
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Fro.  2.  Fibrinolysis  by PMNs; effects of Con A and PMA. Purified  PMNs (5 x  105) were 
plated in ~25I-fibrin-coated wells in  1 ml Dulbecco's MEM supplemented with 5% of FBS 
(@  @) or 5% of plasminogen-depleted  FBS (O- - -O). Con A and PMA were present at 
the indicated  concentration  throughout the period of fibrinolysis  measurements. Fibrino- 
lysis was estimated by assaying aliquots of the medium for solubilized radioactivity at the 
indicated  times. 
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over 90% were viable, by 5 h  only 10% still excluded trypan blue. Hence stimuli 
that evoked plasminogen-dependent fibrinolysis gave no evidence of cell damage 
for many hours; in contrast,  conditions giving rise to a  plasminogen-independ- 
ent fibrinolysis produced cell death within a  few hours.  On the other hand, the 
slow loss of viability that occurs during prolonged incubation of untreated PMNs 
did not lead to enzyme release because there was no detectable increase either in 
plasminogen-independent  or  plasminogen-dependent  fibrinolysis  under  these 
conditions. 
Secretion  of Plasminogen Activator.  CM  from cultures  of purified  PMNs 
contained plasminogen activator, as shown by the capacity to catalyze plasmin- 
ogen-dependent  fibrin  degradation.  The amount of enzyme secreted  increased 
with time, and secretion was stimulated by Con A  (10  -7 M) or low concentrations 
of PMA  (8  x  10  -1° M)  (Fig.  3).  Both the spontaneous and the Con A- or PMA- 
stimulated  production of plasminogen activator were decreased by addition  of 
actinomycin  D  or  cycloheximide  (Table  I),  suggesting  that  maintenance  of 
RNA and protein synthesis were required for initiation of enzyme secretion. 
Glucocorticoids  inhibit  the  production  of plasminogen  activator  by various 
cell types in  culture,  including  hepatoma cell lines  (19),  human  embryo lung 
fibroblasts  (20),  rat  tongue  organ  culture  (21),  and,  in  particular,  mouse 
peritoneal macrophages (5). The same was true for enzyme secretion by human 
PMNs  (Table  I).  The  data  in  Fig.  4  show  a  dose-response  curve  for  the 
dexamethasone  effect  on  enzyme  secretion  by  unstimulated  and  by  Con  A- 
treated  PMNs:  significant  inhibition  was  detected  at  drug  concentrations  as 
low  as  10 -1°  M,  and  50%  inhibition  was  observed  at  approximately  10  -9  M. 1698  • POLYMORPHONUCLEAR  LEUKOCYTE 
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Fro.  3.  Time-course of the effect of Con A and PMA on plasminogen  activator secretion 
by PMNs.  PMNs (1  x  107) were cultured in 1 ml Dulbecco's medium supplemented with 
1% plasminogen-depleted  AT-FBS, in the presence or absence of Con A or PMA. Aliquots 
of CM were collected at the indicated  times and 10 btl assayed for plasminogen activator 
activity,  as  described  in  Materials  and  Methods.  Control,  $  0;  Con A,  (10  -7  M), 
"-  l; PMA  (8 x  10  -1° M) •  •. 
TABLE  I 
Effect of Inhibitors on the Secretion of Plasminogen Activator and Elastase by PMNs* 
Inducer added:  -  Con A, 10  -~ M  PMA,  8  x  10  -~° M  PMA,  1.6  ×  10  -~ M 
Plasminogen present:  +  -  +  +  -  +  - 
-  6.1  0.2  62.8  0.2  12.6  O.1  42  40 
Actinomycin  D, 5  /~g/ml  3.2  0.6  9.8  0.3  4.2  0.2  40  39 
Cycloheximide,  10 ~¢g/ml  2.5  0.4  17.4  0.2  5.5  0.3  39  40 
Dibutyryl cAMP, i0  -s M  2.3  0.2  4.0  0.2  3.0  O.l  46  44 
Theophylline, 10  -~ M  5.4  0.3  7.4  0.3  3.8  0.2  41  36 
Cholera toxin,  10  +9 M  2.0  0.2  4.5  0.2  6.0  0.1  44  38 
Dexamethasone,  10  -7 M  2.6  0.2  12.8  0.2  4.2  0.2  40  38 
Purified PMNs  (1  ×  107) were incubated in 1 ml Dulbecco's MEM supplemented with 1% plasminogen-depleted  AT-FBS in the 
presence  or absence  of drugs.  After 3  h  Con A  or PMA were added.  6 h  later CM was collected  and 10 ~l of the samples were 
assayed for plasminogen-dependent  and independent activity on ~I-fibrin  plates  (4 h  assay). 
* Substrate  solubilized, %. 
Other  steroids  were  also  tested,  and  the  effective  concentrations  for  50% 
inhibition  of plasminogen  activator  secretion  were:  hydrocortisone,  10  -s  M; 
deoxycorticosterone,  progesterone,  >10 -s  M;  fl-estradiol  >10 -5  M.  The  inhibi- 
tory effect of dexamethasone occurred rapidly: it could be detected as early as 1 
h  after drug addition and persisted for at least 10 h. 
Cyclic AMP and related compounds also affect the production of plasminogen 
activator: cAMP stimulates enzyme production by ovarian granulosa cells (22), 
and  inhibits  enzyme  production  by  macrophages  (5).  Enzyme  secretion  by 
PMNs, whether or not stimulated by Con A or PMA, was inhibited by dibutyryl 
cAMP, by theophylline, and by cholera toxin, an adenyl-cyclase stimulant that 
increases  cAMP  levels  in  many cell types,  including  PMNs  (23;  Table I).  In 
contrast,  neither cGMP,  dibutyryl cGMP,  nor 8-bromo-cGMP affected enzyme 
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Fro.  4.  Secretion of plasminogen activator by PMNs; effect of dexamethasone.  Purified 
PMNs (5 x  l0  s) were cultured in 1 ml Dulbecco's MEM supplemented with 1% plasminogen- 
depleted AT-FBS,  in the presence or absence of various concentrations of dexamethasone. 
After 2  h,  some  of the cultures  received Con A  (10 -7 M): the CM  was collected from all 
cultures 6  h  later,  and assayed for plasminogen activator as  described in Methods.  The 
results are expressed as percentages of the plasminogen activator activity present in CM 
from dexamethasone-free cultures. Control,  ©  O; Con A, •  @. 
TABLE  II 
Plasminogen Activator Production by Individual PMNs 
Cells surrounded by lytic zone 
% of total 
-  Dexamethasone 10  -7 M 
Control  21  9 
Con A, 10  -~ M  66  17 
PMA, 8  x  10 -lo M  55  14 
PMNs  (5  x  l03)  were  plated  in  60-mm  tissue  culture  dishes.  After 
incubation with drugs  (see Materials and Methods), the cultures were 
washed and overlaid with a  casein-agar mixture.  Cultures were fixed 
and stained 5 h  later. The results are expressed as the percent of cells 
surrounded by a  lytic zone.  200 cells were scored in each of triplicate 
cultures. 
The  proportion  of  cells  that  secreted  plasminogen  activator  in  different 
experiments  was  determined  by  using  a  casein-agar  overlay  procedure  that 
permits  detection  of  proteolysis  by  individual  cells.  The  results  in  Table  II 
demonstrate  that  the  proportion  of cells surrounded  by lytic zones was  increased 
by  Con  A  and  PMA  (8  x  10  -1°  M),  and  decreased  by  dexamethasone;  in 1700  POLYMORPHONUCLEAR  LEUKOCYTE  PLASMINOGEN  ACTIVATOR 
Fro.  5.  Identification  of plasminogen  activator  and elastase  after  SDS-polyacrylamide 
gel electrophoresis of CM and cell lysate from PMNs. CM from 1 x 106 purified PMNs col- 
lected after 8 h of incubation, and cell lysate from 1.5 x  108 cells lysed in the presence or 
absence of soybean trypsin  inhibitor  and N-acetyl-(ala)4 chloromethyl ketone, were elec- 
trophoresed  in  an  SDS-11% polyacrylamide gel, and the  gel processed for detection  of 
fibrinolytic activity  either  in the presence (A) or in the absence (B) of plasminogen,  as 
described in Materials and Methods. The figure is a photograph of the amido-black stained 
fibrin-agar layer. The clear areas are due to lysis of fibrin in the agar gel by proteases. The 
arrow indicates plasminogen activator. 
addition to their effect on the fraction of enzyme-producing cells, these agents 
also  influenced  the  size  of the  individual  lytic  zones,  whose  diameter  was 
increased by Con A  or PMA and decreased in the presence of dexamethasone. 
No lytic zones were ever observed in the  absence of plasminogen,  even when 
the  cells  were  treated  with  high  concentrations  of  PMA  (1.6  x  10  -8  M), 
showing both that the digestion of casein was due to the secretion of plasmino- 
gen  activator,  and  that  the  assay  performed  under  these  conditions  did  not 
detect the plasminogen-independent proteolytic activity. Plasminogen activator 
production was not restricted to a  subpopulation of PMNs because at least 66% 
of these cells secreted the enzyme. 
The  plasminogen  activator  present  in  CM  could  be  identified  after  SDS- 
polyacrylamide gel electrophoresis  (Fig.  5).  The apparent molecular weight of 
the  enzyme-approximately 60,000-was  comparable  to  that  of plasminogen 
activators  secreted  by other human  cells,  such  as  human embryo lung fibro- 
blasts,  or human osteosarcoma and rhabdomyosarcoma cell lines  (A.  Granelli- m 
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FIG. 6.  Elastolytic  activity  of CM  and cell  lysates from PMNs. PMNs  (1.3 x  l0  s) were 
plated in 1 ml Dulbecco's MEM  supplemented with 1% plasminogen-depleted  AT-FBS. 
After 3 h of  incubation in the presence or absence of  Con A or PMA, CM was collected  and 
the cells  resuspended and lysed in presence of 0.5% Triton X-100. 100-/~I  samples were 
assayed for 6 h for elastolytic  activity  using Sepharose-bound ~25I-elastase  as described in 
Materials and Methods. 
Piperno,  unpublished observations).  The enzyme appeared to be the same in 
CM from unstimulated, or Con A- or PMA-treated cultures. 
Release  of Elastase.  As  noted above,  CM  from control  cultures of PMNs 
or from those incubated in the presence of Con A (10 -7 M) or low concentrations 
of PMA  (8  x  10  -1°  M)  did not promote plasminogen-independent proteolysis; 
however, higher concentrations of PMA (1.6  x  10  -s M) caused the appearance 
of such  an  activity (Table  I).  This  plasminogen-independent component was 
characterized by its susceptibility to a spectrum of protease inhibitors: diisopro- 
pylfluorophosphate (DFP; 1 mM), soybean trypsin inhibitor (100 ~g/ml), and a 
specific inhibitor of elastaselike enzymes, N-acetyl-(ala)4-chloromethyl ketone 
(5  mM),  all  inhibited plasminogen-independent fibrinolysis by  over  85%; in 
contrast, N-a-p-tosyl-L-lysine  chloromethyl ketone  (TLCK; 10 mM),  L-l-tosyl- 
amide-2-phenylethyl-chloromethyl ketone  (TPCK;  10  mM),  and  Trasylol  (10 
Kallikrein inactivator units/ml) were without effect. On this basis, we tenta- 
tively assigned the plasminogen-independent fibrinolytic activity to elastase, a 
known human leukocyte enzyme that is reported to be present in the azurophil 
granules (24). 
In addition, using a sensitive and specific assay for elastase (20), we confirmed 
that the elastolytic activity of CM and cell lysates was unaffected by Con A or 
low concentrations of PMA (8 x  10  -1° M), whereas exposure to higher concentra- 
tions of PMA (1.6  x  10  -~ M) caused the treated cells to release 40% of the total 
elastase  within 3  h  (Fig.  6).  By comparing the  elastolytic activity of PMN 
lysates with known amounts of commercial pancreatic elastase, we estimated 
that  1  x  10  s  human  PMNs  contain  the  equivalent of 0.02  U  of pancreatic 
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In contrast to the secretion of plasminogen activator, the release of elastase 
induced by PMA (1.6  ×  10  -8 M) was completely insensitive to dibutyry] cAMP, 
theophylline, cholera toxin, or dexamethasone, as well as to actinomycin D or 
cycloheximide, suggesting that this enzyme was not being actively synthesized 
by the cells (Table I). 
Proteolytic Activity of Cell Lysates.  Both plasminogen activator and elastase 
could be identified after electrophoretic analysis of  cell lysates in SDS-polyacryl- 
amide gels  (Fig.  5).  Plasminogen activator could be detected only if the cell 
lysates  were  prepared  in  the  presence  of  elastase  inhibitors,  presumably 
because  it  was  otherwise  exposed  to  proteolytic  degradation  by  elastase. 
Plasminogen activator in cell extract migrated as  a  single band of the same 
apparent  molecular weight  as  enzyme from  CM  (60,000), whereas  elastase 
migrated as three bands with apparent molecular weights ranging from 33,000 
to 28,000; these corresponded well to the molecular weights reported for three 
elastase isozymes isolated from granules of human myeloid leukemia cells (7). 
That  the  three  plasminogen-independent bands  of proteolysis  were  due  to 
elastase was inferred from their absence when the gels were developed for fi- 
brinolytic activity in the presence of  N-acetyl-(ala)4-chloromethyl  ketone, a spe- 
cific inhibitor of elastase. 
Other Enzymes.  Alkaline phosphatase, fl-glucuronidase, and lysozyme were 
assayed in CM and cell lysates from cultures of purified PMNs. Neither Con A 
(10 -7 M) nor low concentrations of PMA (8  x  10  -1° M) caused the release of any 
of these enzymes, in contrast to their effect on plasminogen activator secretion. 
Higher  concentrations  of PMA  (1.6  x  10  -s  M;  2-h  incubation)  caused  the 
release of over 50% of the lysozyme present in the cells, reduced the alkaline 
phosphatase content of cell lysates by more than 50%, but did not stimulate the 
release of significant amounts of ~-glucuronidase. 
Discussion 
Human PMNs  are  rich  in  proteolytic enzymes whose maximal activity is 
expressed at neutral pH; they contain collagenase (9), elastase (7), and chymo- 
trypsinlike  enzymes  (8). Our  data  establish  the  formation  of yet  another 
neutral protease by these cells,  plasminogen activator. The demonstration of 
PMN  plasminogen activator was  achieved by experimental approaches  that 
avoided the problem of degradation associated with the high levels of  nonspecific 
proteases in these cells: (a) selective secretion of plasminogen activator could 
be  stimulated in  culture  either by  Con  A  or  by very low  concentrations of 
PMA, without concomitant release of elastase or any other detectable protease, 
and (b) plasminogen activator could be identified in lysates of PMNs provided 
that the cell extracts were prepared with protective concentrations of elastase 
inhibitors. 
The  synthesis and secretion of plasminogen activator by PMNs  should be 
considered both in relation to the other proteases and to the biological properties 
of these cells. Several of the results obtained so far suggest that plasminogen 
activator may occupy a unique position among the proteases of PMNs: 
(a)  The  stimulation  of  plasminogen  activator  production  was  the  most 
sensitive of the PMN responses to Con A  and PMA.  Although both of these 
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phagocytosis (27, 28), and cause microtubule assembly, labilization of specific 
granules, and lysozyme release (29-31), all of these effects require concentra- 
tions of Con A and PMA that are 10- to 1000-fold higher than those yielding 
optimal stimulation of plasminogen activator secretion. Furthermore, maximal 
plasminogen activator secretion occurred without degranulation either of the 
collagenase-containing specific granules or of the azurophil granules in which 
elastase and other neutral proteases are located. It is  also noteworthy that 
concentrations of PMA that  caused release of elastase were associated with 
prompt  and  extensive  loss  of cell  viability,  whereas  those  that  enhanced 
plasminogen activator production were not. All of these facts indicate that the 
storage and release of plasminogen activator are controlled differently than 
they are for the other proteases. 
(b)  Synthesis and secretion of PMN plasminogen activator were inhibited by 
actinomycin and by cycloheximide and puromycin (unpublished results). This 
indicates that both RNA and protein synthesis are needed to sustain continuing 
production of plasminogen activator, and it is again in contrast to the metabo- 
lism of the other granule-associated proteases. The release of elastase, when it 
occurred, was not affected by either actinomycin or cycloheximide; and it is 
known that the synthesis of the granule-associated components takes place in 
the bone marrow and is completed before PMNs enter the circulation, namely, 
at the promyelocyte and myelocyte stages, respectively, for the azurophil and 
specific  granules  (32). Hence,  plasminogen activator differs from the  other 
known PMN proteases also in its pattern of synthesis. 
(c) A  third property that sets plasminogen activator apart from the other 
leukocyte proteinases is the response to glucocorticoids. The action of glucocor- 
ticoids on PMN biology in vitro has been the subject of many studies, and some 
effects have been reported (33); however, with the exception of the inhibition of 
murine granulopoiesis in culture (34), all of these effects have required steroid 
concentrations  103  to  104-fold higher  than  those  that  inhibit  plasminogen 
activator production. It is therefore significant (1) that plasminogen activator 
secretion is inhibited at very low steroid concentrations, comparable to those 
present in the body fluids under physiological conditions; (2) that the release of 
elastase and other enzymes, when it occurred, was not influenced by steroids; 
and (3) that the relative potencies of the steroids tested reflected their known 
anti-inflammatory potencies in vivo (35). 
All of the above observations suggest that plasminogen activator synthesis is 
probably relevant both  to  PMN  function in  inflammation and  to  the  anti- 
inflammatory effects of glucocorticoids.  Although we  do  not  yet  know  the 
significance of plasminogen activator for PMN physiology, the following work- 
ing hypothesis appears to provide a reasonable focus for further tests.  4 Because 
This hypothesis requires a  modification of the prevailing view that PMNs  are terminally 
differentiated end products devoid of significant genetic transcription and minimally active in 
translation -  the biosynthetic equivalents of nucleated erythrocytes or platelets.  We provide the 
experimental basis for the proposed modification in a  manuscript soon to be submitted to this 
journal; it shows that the majority of human peripheral blood PMNs actively synthesize RNA 
and  protein,  a  substantial  fraction  of which  is  secreted  under  conditions  of short-term  cell 
culture.  That cultured PMNs are able to synthesize products destined for secretion has already 
been suggested by the effects of inhibitors of RNA  and protein synthesis on the secretion of 
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release of elastase and other proteases is not linked to genetic transcription or 
translation, is unaffected by steroids, and is associated with prompt loss of cell 
viability, we suggest that  these enzymes are  a  static part  of the  enzymatic 
equipment  of  PMNs,  and  are  destined  to  function  only  intracellularly  in 
conjunction with endocytosis. In contrast, because plasminogen activator pro- 
duction requires RNA and protein synthesis, and is sensitive to low concentra- 
tions of glucocorticoids, we propose (a) that the synthesis of this enzyme forms 
part of the response of PMNs  to  as yet unidentified extracellular stimuli or 
mediators, and (b) that its normal function is expressed in the local microenvi- 
ronment after secretion by PMNs.  We have previously summarized a  body of 
evidence suggesting that the action of plasmin, locally generated by synthesis 
and secretion of plasminogen activator, forms an essential part of the mecha- 
nism of macrophage migration (5). All of these considerations, and a  parallel 
body of supporting evidence, lead to the inference that the same may hold for 
PMNs; these cells, like macrophages, are  migratory, are recruited to sites of 
inflammation, and their accumulation at such sites is blocked by glucocorticoids 
(38). In view of the parallel effects of glucocorticoids on macrophages, these re- 
sults reinforce the proposal that the anti-inflammatory  effects of corticosteroids 
are  mediated,  in part,  through specific reductions in  plasminogen activator 
secretion by both PMNs and macrophages, with secondary inhibition of their 
migration. If this hypothesis is correct,  plasminogen activator secretion may 
provide a convenient assay for identifying and isolating the putative mediators 
responsible for recruiting inflammatory cells (39). 
Summary 
Purified  human  PMNs  secrete  plasminogen  activator.  This  secretion  is 
stimulated by Con A and low concentrations of PMA, and is inhibited by low 
concentrations of glucocorticoids, and by cAMP, actinomycin D, and cyclohexi- 
mide. In contrast, the release of granule-bound enzymes, such as elastase, is 
achieved only at higher concentrations of PMA, and is not affected by any of the 
inhibitors that block plasminogen activator production. 
These results show that the production of plasminogen activator by PMNs is 
controlled by  agents that  affect inflammations, and that this  control  is  not 
shared by other lytic enzymes known to be associated with these cells.  This 
suggests a particular role for plasminogen activator in the response pattern of 
PMNs  and also supports the concept,  previously developed for macrophages, 
that the secretion of this enzyme is correlated with cell migration in vivo. 
We thank Ms.  Virginia Iliescu,  Mrs.  Atsuko Horiuchi,  and Ms.  Anne McGinley for excellent 
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